Protection against FIV challenge infection by genetic vaccination using minimalistic DNA constructs for FIV env gene and feline IL-12 expression

被引:33
作者
Boretti, FS
Leutenegger, CM
Mislin, C
Hofmann-Lehmann, R
König, S
Schroff, M
Junghans, C
Fehr, D
Huettner, SW
Habel, A
Flynn, JN
Aubert, A
Pedersen, NC
Wittig, B
Lutz, H
机构
[1] Univ Zurich, Clin Lab, Dept Vet Internal Med, CH-8057 Zurich, Switzerland
[2] Mologen, Berlin, Germany
[3] Inst Pasteur, Unite Virol Mol, Paris, France
[4] Univ Glasgow, Retrovirus Lab, Dept Vet Pathol, Glasgow, Lanark, Scotland
[5] Labs Virbac SA, Nice, France
[6] Univ Calif Davis, Sch Vet Med, Dept Med & Epidemiol, Davis, CA 95616 USA
[7] Free Univ Berlin, Inst Mol Biol & Biochem, Fachbereich Human Med, D-1000 Berlin, Germany
关键词
DNA vaccine; feline IL-12; FIV env gene; protection;
D O I
10.1097/00002030-200008180-00009
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Objective: To evaluate the efficacy of a genetic vaccination protocol based on minimalistic, immunogenic defined gene expression (MIDGE) vectors coding for domains of the feline immunodeficiency virus (FIV) env gene and feline IL-12. Methods: Three groups of four cats each were immunized three times within 6 weeks by the ballistic transfer of gold particles coated with MIDGE vectors. Group 1 received non-coated gold beads, groups 2 and 3 MIDGE vectors expressing FIV surface plus part of the transmembrane protein. In addition, group 3 received feline IL-12 DNA. All cats were challenged by intraperitoneal injection of 25 TCID50 of infectious FIV Z2. The following criteria were monitored: clinical signs, antibodies to transmembrane protein, antibodies to whole FIV, haematological parameters and kinetics of CD4 and CD8 cells, FIV proviral load (determined by quantitative polymerase chain reaction; PCR) and cytotoxic T lymphocyte (CTL) activity (in selected cats). Results: None of the cats developed a detectable antibody response during immunizations. Four weeks after challenge exposure, all cats in group 1 (control) and group 2 (FIV surface-transmembrane protein) had seroconverted and showed a high proviral load until week 19 (end of experiment). In contrast, only one of four cats in group 3 (surface-transmembrane protein and IL-12) showed antibodies; it was provirus positive at reduced virus load. Short-lived CTL activity was found in two cats in group 3. Conclusion: Genetic vaccination using a MIDGE-based construct for the expression of the surface-transmembrane protein domain of FIV env and feline IL-12 DNA led to protection against homologous virus challenge in three out of four vaccinated cats. (C) 2000 Lippincott Williams & Wilkins.
引用
收藏
页码:1749 / 1757
页数:9
相关论文
共 60 条
[31]   Potent, protective anti-HIV immune responses generated by bimodal HIV envelope DNA pins protein vaccination [J].
Letvin, NL ;
Montefiori, DC ;
Yasutomi, Y ;
Perry, HC ;
Davies, ME ;
Lekutis, C ;
Alroy, M ;
Freed, DC ;
Lord, CI ;
Handt, LK ;
Liu, MA ;
Shiver, JW .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1997, 94 (17) :9378-9383
[32]   Rapid feline immunodeficiency virus provirus quantitation by polymerase chain reaction using the TaqMan® fluorogenic real-time detection system [J].
Leutenegger, CM ;
Klein, D ;
Hofmann-Lehmann, R ;
Mislin, C ;
Hummel, U ;
Böni, J ;
Boretti, F ;
Guenzburg, WH ;
Lutz, H .
JOURNAL OF VIROLOGICAL METHODS, 1999, 78 (1-2) :105-116
[33]   Partial protection by vaccination with recombinant feline immunodeficiency virus surface glycoproteins [J].
Leutenegger, CM ;
Hofmann-Lehmann, R ;
Holznagel, E ;
Cuisinier, AM ;
Wolfensberger, C ;
Duquesne, V ;
Cronier, J ;
Allenspach, K ;
Aubert, A ;
Ossent, P ;
Lutz, H .
AIDS RESEARCH AND HUMAN RETROVIRUSES, 1998, 14 (03) :275-283
[34]   Quantitative real-time PCR for the measurement of feline cytokine mRNA [J].
Leutenegger, CM ;
Mislin, CN ;
Sigrist, B ;
Ehrengruber, MU ;
Hofmann-Lehmann, R ;
Lutz, H .
VETERINARY IMMUNOLOGY AND IMMUNOPATHOLOGY, 1999, 71 (3-4) :291-305
[35]   Controlling HIV pathogenesis: The role of the noncytotoxic anti-HIV response of CD8(+) T cells [J].
Levy, JA ;
Mackewicz, CE ;
Barker, E .
IMMUNOLOGY TODAY, 1996, 17 (05) :217-224
[36]   Protection against tuberculosis by a plasmid DNA vaccine [J].
Lowrie, DB ;
Silva, CL ;
Colston, MJ ;
Ragno, S ;
Tascon, RE .
VACCINE, 1997, 15 (08) :834-838
[37]   USE OF DNAS EXPRESSING HIV-1 ENV AND NONINFECTIOUS HIV-1 PARTICLES TO RAISE ANTIBODY-RESPONSES IN MICE [J].
LU, S ;
SANTORO, JC ;
FULLER, DH ;
HAYNES, JR ;
ROBINSON, HL .
VIROLOGY, 1995, 209 (01) :147-154
[38]   Simian immunodeficiency virus DNA vaccine trial in macaques [J].
Lu, S ;
Arthos, J ;
Montefiori, DC ;
Yasutomi, Y ;
Manson, K ;
Mustafa, F ;
Johnson, E ;
Santoro, JC ;
Wissink, J ;
Mullins, JI ;
Haynes, JR ;
Letvin, NL ;
Wyand, M ;
Robinson, HL .
JOURNAL OF VIROLOGY, 1996, 70 (06) :3978-3991
[39]   Vaccination of cats with recombinant envelope glycoprotein of feline immunodeficiency virus: Decreased viral load after challenge infection [J].
Lutz, H ;
HofmannLehmann, R ;
Leutenegger, C ;
Allenspach, K ;
Cuisinier, AM ;
Cronier, J ;
Duquesne, V ;
Aubert, A .
AIDS RESEARCH AND HUMAN RETROVIRUSES, 1996, 12 (05) :431-433
[40]   SPECIFICITY ASSESSMENT OF FELINE T-LYMPHOTROPIC LENTIVIRUS SEROLOGY [J].
LUTZ, H ;
ARNOLD, P ;
HUBSCHER, U ;
EGBERINK, H ;
PEDERSEN, N ;
HORZINEK, MC .
JOURNAL OF VETERINARY MEDICINE SERIES B-ZENTRALBLATT FUR VETERINARMEDIZIN REIHE B-INFECTIOUS DISEASES AND VETERINARY PUBLIC HEALTH, 1988, 35 (10) :773-778